LifeGel
Surgical Hemostasis (esp. in spine surgery where swelling cannot be tolerated)
Key Facts
About Medcura
Medcura is a private, clinical-stage medical device company pioneering a novel biomaterial platform for surgical hemostasis. Its core technology is based on hydrophobically modified chitosan, engineered to control bleeding via mucoadhesion without problematic swelling, addressing a critical unmet need in confined surgical spaces like spine procedures. The company's lead product, LifeGel, has received FDA Breakthrough Device Designation and positions Medcura to disrupt the multi-billion dollar biosurgery market with a safer, more cost-effective alternative to existing agents. Medcura appears to be pre-revenue, actively developing its pipeline and building a world-class surgical advisory board.
View full company profile